Global Leading Market Research Publisher QYResearch announces the release of its latest report “Cell Cryopreservation Solution – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Cell Cryopreservation Solution market, including market size, share, demand, industry development status, and forecasts for the next few years.
For cell therapy manufacturers, biobanks, and research laboratories, maintaining cell viability, functionality, and sterility during long-term storage at cryogenic temperatures (typically -80°C to -196°C) remains a critical challenge. Traditional cryopreservation methods using dimethyl sulfoxide (DMSO) and fetal bovine serum (FBS) can cause cell damage from ice crystal formation, osmotic shock, and oxidative stress, resulting in reduced post-thaw viability (typically 50-80% for sensitive cell types) and altered cell function. Cell cryopreservation solutions address these challenges by incorporating optimized cryoprotectants (DMSO, glycerol, ethylene glycol, or non-toxic alternatives such as ectoin or hydroxyethyl starch), nutrients, buffers, and preservatives to protect cells during freezing and thawing processes, ensuring they remain active and fully functional after long-term storage. With the advancement of biomedicine and cell therapy technology, the global market for cell cryopreservation fluids is experiencing rapid growth, widely used in stem cell research, cell therapy manufacturing and storage, and biobank management. The global market was valued at US122millionin2025andisprojectedtoreachUS122millionin2025andisprojectedtoreachUS 165 million by 2032, growing at a CAGR of 4.5%. This report delivers a data-driven analysis of market size, market share concentration across leading manufacturers, product segmentation (serum-free vs. serum-containing media), and end-user demand drivers across biotechnology companies, research institutes, and hospitals.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5514165/cell-cryopreservation-solution
1. Market Size & Share Outlook: Steady Growth Driven by Cell Therapy Commercialization
The global market for cell cryopreservation solutions is experiencing steady growth, driven by the increasing number of cell therapy product approvals (CAR-T, iPSC-derived therapies), expansion of biobanking infrastructure, and demand for animal-free/serum-free reagents with reduced biological contamination risk and improved lot-to-lot consistency. The market was valued at US122millionin2025andisprojectedtoreachUS122millionin2025andisprojectedtoreachUS 165 million by 2032, representing a CAGR of 4.5%—moderate but stable growth, with serum-free segment growing faster (6-8% CAGR) than serum-containing segment (2-3% CAGR).
Recent market intelligence (Q1 2026): Preliminary supply-side data indicates that market share concentration among the top five manufacturers—Thermo Fisher Scientific (Gibco, HyClone), BioLife Solutions (CryoStor, BloodStor), Fujifilm (Irvine Scientific), Sartorius (CellGenix), and Merck—remains significant at approximately 50-55% of the global market. BioLife Solutions leads the premium serum-free, animal-free segment (CryoStor CS series, US200−500per100mL)forclinicalcelltherapyapplications(CAR−T,NKcell,TILmanufacturing).ThermoFisherandFujifilmdominatetheresearch−gradeandserum−containingsegments(US200−500per100mL)forclinicalcelltherapyapplications(CAR−T,NKcell,TILmanufacturing).ThermoFisherandFujifilmdominatetheresearch−gradeandserum−containingsegments(US 50-150 per 100 mL). Emerging players (Yocon Biology, Selcell, Shanghai Epizyme, ExCell Bio) are gaining market share in the Asia-Pacific region with cost-competitive serum-free formulations (US$ 30-80 per 100 mL).
End-user segmentation: Biotechnology companies (cell therapy developers, contract development and manufacturing organizations/CDMOs) represent the largest and fastest-growing segment (45-50% of market demand), driven by clinical and commercial manufacturing needs. Universities and research institutes (30-35% of demand) represent stable volume for basic research and biobanking. Hospitals (15-20% of demand) focus on point-of-care cell therapy storage (hematopoietic stem cell transplantation, cord blood banking, fertility preservation) and are increasingly adopting serum-free formulations to meet regulatory requirements.
2. Technology Deep Dive: Serum-free vs. Serum-containing Cryopreservation Media
Cell cryopreservation solution is used to preserve living cells or tissue samples at extremely low temperatures. The main purpose of this preservation solution is to prevent cells from being damaged during the freezing and thawing process to ensure that they remain active and fully functional after long-term storage. Typical cell cryopreservatives contain cryoprotectants (to prevent ice crystal formation), nutrients (to maintain cellular energy), buffers (to maintain pH), and preservatives (to prevent contamination). The choice between serum-containing and serum-free formulations has significant implications for cell viability, regulatory compliance, and manufacturing cost.
Market segmentation by formulation type:
- Serum Cell Freezing Medium (~40-45% of market share by volume, declining at 2-3% annually) – Contains fetal bovine serum (FBS) or other animal sera (5-20% v/v) as a source of growth factors, proteins, and cryoprotective agents. FBS provides excellent post-thaw viability (80-95% for robust cell lines like CHO, HEK293, many primary cells) due to its complex mixture of albumin, transferrin, growth factors, and anti-apoptotic factors. Advantages: lower cost (US$ 50-150 per 100 mL), historically validated for thousands of cell types, widely available. Disadvantages: batch-to-batch variability (FBS sourced from multiple animals, lot-dependent performance), risk of biological contamination (viruses, mycoplasma, prions), immunogenicity concerns (xenoantigens transferred with cells), and animal welfare/ethical concerns (FBS collected from bovine fetuses). Serum-containing media are used primarily for research applications, non-clinical biobanking, and veterinary cell therapy. Leading brands: Thermo Fisher Gibco Recovery (with FBS), Fujifilm Irvine Scientific, Merck, Capricorn.
- Serum-free Cell Freezing Medium (dominant and fastest-growing segment, ~55-60% of market share by value, growing at 6-8% CAGR) – Formulated without any animal-derived components. Chemically defined, often containing recombinant or synthetic alternatives: dimethyl sulfoxide (DMSO, 5-10% standard cryoprotectant), hydroxyethyl starch (HES, 5-10%, reduces ice crystal formation), methylcellulose, polyvinylpyrrolidone (PVP), dextran, trehalose (disaccharide, stabilizes membranes), amino acids, vitamins, and antioxidants (N-acetylcysteine, vitamin E). Advantages: batch-to-batch consistency (synthetic, chemically defined), reduced contamination risk (no animal-derived pathogens), regulatory compliance (FDA, EMA prefer defined media for clinical cell therapy), improved safety profile (no xenoantigens), and animal welfare alignment. Disadvantages: higher cost (US$ 200-500 per 100 mL for clinical grade), cell-type dependent viability (some sensitive primary cells show lower viability 50-70% in serum-free vs. 70-85% in serum-containing). Serum-free media are required for clinical cell therapy manufacturing (CAR-T, stem cell therapies) and used for biobanking of clinically banked cells. Leading brands: BioLife Solutions CryoStor (CS5, CS10—5% and 10% DMSO), Sartorius CellGenix (SCM), Fujifilm Irvine Scientific (PRIME-XV), WAK-Chemie Medical (Stem-K). Newer serum-free formulations use non-DMSO cryoprotectants (ectoin, glycerol, propylene glycol) to reduce DMSO toxicity (which can cause clinical adverse reactions when DMSO-preserved cells are infused into patients).
Industry insight (regulatory and clinical segmentation): The cell cryopreservation solution market exhibits a clear product hierarchy based on intended use: Research-grade (serum-containing or undefined serum-free, US30−80per100mL)forbasicresearchandnon−GMPbiobanking;∗∗GMP−grade∗∗(serum−free,chemicallydefined,animal−free,US30−80per100mL)forbasicresearchandnon−GMPbiobanking;∗∗GMP−grade∗∗(serum−free,chemicallydefined,animal−free,US 200-500 per 100 mL) for clinical cell therapy manufacturing, requiring documentation (certificate of analysis, stability data, animal origin-free certificate, sterility test, endotoxin testing, and often viral inactivation validation). GMP-grade products command 3-5x price premium but represent 60-70% of market revenue due to clinical cell therapy expansion (projected 20-25 approved cell therapy products by 2027, up from 10 in 2025).
3. Market Drivers: Cell Therapy Commercialization, Biobanking Expansion, and Animal-free Reagent Demand
Three factors are shaping the cell cryopreservation solution market:
First, increasing number of cell therapy product approvals and commercial manufacturing. As of early 2026, FDA has approved 12 cell and gene therapy products (CAR-T: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma; Carvykti; other: Zolgensma, Hemgenix, Elevidys, etc.), with 50-70 cell therapies in late-stage clinical trials. Commercial manufacturing requires large-scale cryopreservation of patient apheresis material, intermediate cell products, and final drug product. The average CAR-T batch requires 10-20 liters of cryopreservation medium (including wash steps), representing US5,000−20,000inmediacostperbatch.Annualdemandforclinical−grade∗∗cellcryopreservationsolution∗∗fromapprovedcelltherapiesisestimatedatUS5,000−20,000inmediacostperbatch.Annualdemandforclinical−grade∗∗cellcryopreservationsolution∗∗fromapprovedcelltherapiesisestimatedatUS 50-70 million and growing at 20-25% CAGR as new products launch.
Second, expansion of cell and tissue biobanking. Biobanks (public and private) store millions of biospecimens (blood components, stem cells, cord blood, tumor tissue, iPSCs) for research and clinical use. The global biobanking market is projected to reach US50−70billionby2028,withcryopreservationmediarepresenting2−450−70billionby2028,withcryopreservationmediarepresenting2−4 100-200 million annually). Public cord blood banks (250-300 globally) each store 10,000-100,000 cord blood units, each requiring 20-50 mL of cryopreservation medium. Private biobanks (long-term storage for personalized medicine) are growing in Asia-Pacific (China, Japan, South Korea) and Middle East.
Third, increasing demand for animal-free and serum-free reagents. Regulatory agencies (FDA, EMA, China NMPA) strongly encourage (or require for certain product types) the use of animal-free, chemically defined reagents for cell therapy manufacturing to reduce contamination risk, immunogenicity, and batch variability. The International Council for Harmonisation (ICH) Q5A (viral safety evaluation) and Q5D (derivation of cell lines) recommend avoiding animal-derived components. BioLife Solutions, Sartorius, and Fujifilm have captured market share with GMP-grade serum-free formulations compliant with USP <1043> (Auxiliary Materials for Cell Therapy) and EP 5.2.12 (Raw Materials for Cell Therapy). Serum-free market share is projected to reach 65-70% of total market value by 2030.
Typical user case (Q3 2025): A mid-sized CDMO (contract development and manufacturing organization) producing autologous CAR-T therapies for three clinical-stage biotech clients faced challenges with serum-containing cryopreservation medium: batch-to-batch viability variation (65-85% post-thaw), sporadic contamination alerts (3% of incoming FBS lots failed mycoplasma testing), and FDA feedback requesting serum-free process for IND submission. The CDMO switched to a serum-free cell cryopreservation solution (BioLife Solutions CryoStor CS10, 10% DMSO, GMP-grade). Validation on patient-derived apheresis material (n=25) showed post-thaw viability 82-92% (mean 87%), T cell functionality (IFN-γ production, cytotoxicity) comparable to serum-containing medium, and no contamination events (0/25 batches). Media cost increased from US120(serum−containing)toUS120(serum−containing)toUS 400 per 100 mL (serum-free); each batch uses 150 mL (US600vs.US600vs.US 180). However, eliminating FBS testing (US1,000perlotofFBS)andreducingre−workduetoviabilityfailuressavedUS1,000perlotofFBS)andreducingre−workduetoviabilityfailuressavedUS 15,000 per batch. The client successfully filed IND with serum-free process, reducing CMC (chemistry, manufacturing, and controls) risk. The CDMO standardized serum-free cryopreservation across all CAR-T programs.
Policy and regulatory update (2025-2026): The U.S. Pharmacopeia (USP) revised Chapter <1043> “Auxiliary Materials for Cell, Gene, and Tissue-Engineered Products” (December 2025), adding cryopreservation media to the list of materials requiring risk assessment, supplier qualification, and functional testing. The FDA published final guidance (May 2025) “Cryopreservation of Cell and Gene Therapy Products: Considerations for Manufacturing” recommending serum-free, defined media for commercial manufacturing and requiring stability data (12-24 months at -80°C to -196°C) for final drug product. The European Medicines Agency (EMA) adopted “Guideline on Quality and Non-Clinical Requirements for Cell-Based Medicines” (revised 2025) specifying that cryopreservation media should be included in the drug substance/drug product specification, with acceptance criteria for DMSO residual (≤50-100 mg per infusion due to toxicity concerns). China’s National Medical Products Administration (NMPA) updated “Technical Guidelines for Cell Therapy Product Research and Evaluation” (January 2026), requiring GMP-grade, serum-free media for all clinical-stage cell therapies and recommending non-DMSO cryoprotectants for pediatric applications.
4. Competitive Landscape & Regional Market Share Dynamics
The Cell Cryopreservation Solution market is segmented as below:
Key players:
Fujifilm (Japan – Irvine Scientific, PRIME-XV series), Thermo Fisher Scientific (US – Gibco Recovery, HyClone AdvanceSTEM), BioLife Solutions (US – CryoStor CS5/CS10, BloodStor, STEM-CELLBANKER), Sartorius (Germany – CellGenix GMP), Cytiva (US – formerly GE Healthcare), WAK-Chemie Medical (Germany – Stem-K, FertiPro), Zenoaq (Japan), Merck (Germany – Cell Freezing Media), Vitrolife Group (Sweden – Freeze Media for reproductive cells), Lifeline (ISCO – International Stem Cell Corp.), Capricorn (Germany), BioLegend (US), Miltenyi Biotec (Germany), CooperSurgical (US – Fertility Cryo), Yocon Biology (China), Selcell (China), Shanghai Epizyme (China), ExCell Bio (China)
Segment by Type:
- Serum Cell Freezing Medium – 40-45% of market share by volume, declining
- Serum-free Cell Freezing Medium – 55-60% of market share by value, fastest-growing
Segment by End-User:
- Biotechnology Company (cell therapy developers, CDMOs) – 45-50% of demand, fastest-growing
- Universities and Research Institutes – 30-35% of demand
- Hospital (cord blood banks, fertility clinics, transplant centers) – 15-20% of demand
Regional market share estimates 2025 (value):
- North America: 40% (US 37%, Canada 3%) – Largest cell therapy industry, FDA guidance driving serum-free adoption
- Europe: 30% (Germany 8%, UK 6%, France 4%, Switzerland 4%, others 8%) – Strong regulatory framework, EMA guidelines
- Asia-Pacific: 25% (China 12%, Japan 7%, South Korea 3%, Australia 2%, others 1%) – Fastest-growing, domestic manufacturers gaining share
- Rest of World: 5% (Latin America, Middle East)
Exclusive insight (原创观察): A critical and underreported dynamic is the divergence in market share between pre-filled cryopreservation solutions (patient-ready, sterile-filled bags/bottles requiring no preparation) and concentrated solutions requiring dilution (cost-effective but requiring aseptic processing). BioLife Solutions pioneered pre-filled, sterile bags (CryoStor bags in 100-500 mL sizes) for clinical cell therapy manufacturing, reducing contamination risk and technician time (currently 2-3 hours for media preparation vs. 10-15 minutes for pre-filled). Pre-filled formats capture 40-50% of GMP-grade market but cost 2-3x more per mL. Concentrated solutions (e.g., Sartorius CellGenix DMSO solution requiring dilution with albumin or saline) retain market share in smaller research labs and cost-sensitive markets. By 2030, we project pre-filled formats will reach 60-70% of clinical manufacturing demand (GMP-grade) due to regulatory preference for closed-system components, while concentrated formats will remain dominant in research and non-GMP biobanking.
5. Technical Hurdles and Future Research Directions
Despite advances, significant technical challenges remain:
- DMSO toxicity: DMSO (5-10% standard cryoprotectant) causes adverse clinical reactions (nausea, vomiting, cardiac arrhythmias, neurological symptoms) in 20-50% of patients receiving DMSO-cryopreserved cells, especially at high cell doses. DMSO is also cytotoxic to certain cell types (platelets, some primary neurons) during freeze-thaw. Non-DMSO cryoprotectants (ectoin, hydroxyethyl starch plus trehalose, propylene glycol) are being developed but generally show lower viability (50-70% vs. 70-90% for DMSO) for sensitive cell types, limiting adoption.
- Cell-type specific optimization: No universal cryopreservation solution works for all cell types. CAR-T cells (lymphocytes) survive well in 10% DMSO + albumin; hematopoietic stem cells require 5-10% DMSO + HES + dextran; iPSCs and embryonic stem cells require Rho kinase inhibitor (Y-27632) supplementation to prevent apoptosis; oocytes and embryos require slow-freeze protocols with 1.5 M DMSO or ethylene glycol + sucrose. Cell therapy product developers must optimize cryopreservation media for each cell product (costly and time-consuming, 3-6 months per cell type).
- Post-thaw cell function vs. viability: Many cryopreservation solutions achieve 80-90% post-thaw viability by trypan blue exclusion but fail to preserve functional activity (cytotoxicity for CAR-T cells, differentiation capacity for stem cells, antibody secretion for B cells). Functional assays (IFN-γ ELISpot, cytotoxicity killing assays, CFU colony formation) are required for clinical product release but add 3-7 days to testing timeline.
Future Market Research priorities should address:
- Non-DMSO, biocompatible cryoprotectants – Ectoin (from halophilic bacteria) and L-proline (natural osmolyte) show promise with reduced toxicity; formulations under development by BioLife, BioLegend, and academic spinouts; clinical validation studies ongoing
- Intracellular ice formation inhibitors – Ice recrystallization inhibitors (IRIs), including polyvinyl alcohol (PVA) and polyglycerol (PGL) derivatives, reduce ice crystal damage even at slow cooling rates; prototype formulations from University of Minnesota/Warwick spinouts
- Machine learning for formulation optimization – High-throughput cryopreservation screening (96-well format, automated freeze-thaw, viability/function assays) coupled with ML models to predict optimal cryoprotectant combinations for any cell type; reducing development time from 6 months to 2-4 weeks
- Smart cryopreservation bags with integrated monitoring – RFID-enabled bags tracking temperature history (time above -140°C during transport), oxygen exposure, and radiation dose, integrated with blockchain-based cold chain monitoring
- Lyophilized (dry-state) cell preservation – Emerging technologies preserving cells in trehalose glass at room temperature, eliminating liquid nitrogen logistics; prototype for platelets and red blood cells; early stage for nucleated cells (10-20% viability)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
